RANBAXY LAUNCHES GENERIC LIPITOR IN DENMARK

Ranbaxy Laboratories announced it has launched generic Lipitor (atorvastatin) in Denmark.

"The introduction of atorvastatin in Denmark is a significant milestone in Ranbaxy's atorvastatin strategy and heralds the beginning of the company's determined efforts to bring affordable atorvastatin to patients in Europe and other parts of the world," Malvinder Mohan Singh, CEO and managing director of Ranbaxy, said. "Generic atorvastatin will bring significant and immediate cost benefits to the Danish healthcare system."

Ranbaxy said it will continue to actively pursue all options in the European Union and in other markets in order to bring affordable atorvastatin to patients around the world.

The company recently won a Canadian patent case, bring it a step closer to launching generic Lipitor there, but it lost a similar case in the European Patent Office.

Ranbaxy also announced that its German subsidiary Basics has had its products listed by Allgemeine Ortskrankenkassen, a health insurer that represents roughly 35 percent of all health insurance policyholders in Germany. The listing applies to 43 molecules and combination drugs.